• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4602291)   Today's Articles (42)   Subscriber (49368)
For: Patel SR, Jenkins J, Papadopolous N, Burgess MA, Plager C, Gutterman J, Benjamin RS. Pilot study of vitaxin--an angiogenesis inhibitor-in patients with advanced leiomyosarcomas. Cancer 2001;92:1347-8. [PMID: 11571751 DOI: 10.1002/1097-0142(20010901)92:5<1347::aid-cncr1456>3.0.co;2-0] [Citation(s) in RCA: 78] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Number Cited by Other Article(s)
51
Cai W, Sam Gambhir S, Chen X. Multimodality tumor imaging targeting integrin αvβ3. Biotechniques 2005;39:S14-25. [DOI: 10.2144/000112091] [Citation(s) in RCA: 49] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]  Open
52
Akalu A, Cretu A, Brooks PC. Targeting integrins for the control of tumour angiogenesis. Expert Opin Investig Drugs 2005;14:1475-86. [PMID: 16307488 DOI: 10.1517/13543784.14.12.1475] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
53
Rehman S, Jayson GC. Molecular imaging of antiangiogenic agents. Oncologist 2005;10:92-103. [PMID: 15709211 DOI: 10.1634/theoncologist.10-2-92] [Citation(s) in RCA: 112] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]  Open
54
Kuphal S, Bauer R, Bosserhoff AK. Integrin signaling in malignant melanoma. Cancer Metastasis Rev 2005;24:195-222. [PMID: 15986132 DOI: 10.1007/s10555-005-1572-1] [Citation(s) in RCA: 213] [Impact Index Per Article: 11.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
55
Verheul HMW, Pinedo HM. Inhibition of angiogenesis in cancer patients. Expert Opin Emerg Drugs 2005;10:403-12. [PMID: 15934875 DOI: 10.1517/14728214.10.2.403] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
56
Sangro B, Mazzollini G, Prieto J. Future therapies for hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2005;17:515-21. [PMID: 15827441 DOI: 10.1097/00042737-200505000-00007] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/10/2022]
57
Verheul HMW, Pinedo HMW. Angiogenesis inhibitors: what is the clinical future? PROGRESS IN DRUG RESEARCH. FORTSCHRITTE DER ARZNEIMITTELFORSCHUNG. PROGRES DES RECHERCHES PHARMACEUTIQUES 2005;63:67-91. [PMID: 16265877 DOI: 10.1007/3-7643-7414-4_4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/05/2023]
58
Akhtar N, Padilla ML, Dickerson EB, Steinberg H, Breen M, Auerbach R, Helfand SC. Interleukin-12 inhibits tumor growth in a novel angiogenesis canine hemangiosarcoma xenograft model. Neoplasia 2004;6:106-16. [PMID: 15140399 PMCID: PMC1502086 DOI: 10.1593/neo.03334] [Citation(s) in RCA: 55] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
59
Hwang R, Varner J. The role of integrins in tumor angiogenesis. Hematol Oncol Clin North Am 2004;18:991-1006, vii. [PMID: 15474331 DOI: 10.1016/j.hoc.2004.09.010] [Citation(s) in RCA: 78] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
60
Trikha M, Zhou Z, Nemeth JA, Chen Q, Sharp C, Emmell E, Giles-Komar J, Nakada MT. CNTO 95, a fully human monoclonal antibody that inhibits alphav integrins, has antitumor and antiangiogenic activity in vivo. Int J Cancer 2004;110:326-35. [PMID: 15095296 DOI: 10.1002/ijc.20116] [Citation(s) in RCA: 126] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
61
Trochon-Joseph V, Martel-Renoir D, Mir LM, Thomaïdis A, Opolon P, Connault E, Li H, Grenet C, Fauvel-Lafève F, Soria J, Legrand C, Soria C, Perricaudet M, Lu H. Evidence of antiangiogenic and antimetastatic activities of the recombinant disintegrin domain of metargidin. Cancer Res 2004;64:2062-9. [PMID: 15026344 DOI: 10.1158/0008-5472.can-03-3272] [Citation(s) in RCA: 77] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
62
Miller KD. Recent translational research: antiangiogenic therapy for breast cancer - where do we stand? Breast Cancer Res 2004;6:128-32. [PMID: 15084233 PMCID: PMC400679 DOI: 10.1186/bcr782] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2004] [Accepted: 03/04/2004] [Indexed: 01/13/2023]  Open
63
Jin H, Varner J. Integrins: roles in cancer development and as treatment targets. Br J Cancer 2004;90:561-5. [PMID: 14760364 PMCID: PMC2410157 DOI: 10.1038/sj.bjc.6601576] [Citation(s) in RCA: 417] [Impact Index Per Article: 20.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]  Open
64
Eskens FALM. Angiogenesis inhibitors in clinical development; where are we now and where are we going? Br J Cancer 2004;90:1-7. [PMID: 14710197 PMCID: PMC2395335 DOI: 10.1038/sj.bjc.6601401] [Citation(s) in RCA: 146] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2003] [Revised: 09/04/2003] [Accepted: 09/12/2003] [Indexed: 11/30/2022]  Open
65
Puduvalli VK. Inhibition of angiogenesis as a therapeutic strategy against brain tumors. Cancer Treat Res 2004;117:307-36. [PMID: 15015567 DOI: 10.1007/978-1-4419-8871-3_18] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/29/2023]
66
Espinosa E, Zamora P, Feliu J, González Barón M. Classification of anticancer drugs—a new system based on therapeutic targets. Cancer Treat Rev 2003;29:515-23. [PMID: 14585261 DOI: 10.1016/s0305-7372(03)00116-6] [Citation(s) in RCA: 82] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
67
Patel SR. Recent advances in systemic therapy of soft tissue sarcomas. Expert Rev Anticancer Ther 2003;3:179-84. [PMID: 12722877 DOI: 10.1586/14737140.3.2.179] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
68
Schraa AJ, Kok RJ, Moorlag HE, Bos EJ, Proost JH, Meijer DKF, de Leij LFMH, Molema G. Targeting of RGD-modified proteins to tumor vasculature: a pharmacokinetic and cellular distribution study. Int J Cancer 2002;102:469-75. [PMID: 12432548 DOI: 10.1002/ijc.10727] [Citation(s) in RCA: 55] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
69
Kaban K, Herbst RS. Angiogenesis as a target for cancer therapy. Hematol Oncol Clin North Am 2002;16:1125-71. [PMID: 12512387 DOI: 10.1016/s0889-8588(02)00047-3] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
70
Scappaticci FA. Mechanisms and future directions for angiogenesis-based cancer therapies. J Clin Oncol 2002;20:3906-27. [PMID: 12228212 DOI: 10.1200/jco.2002.01.033] [Citation(s) in RCA: 181] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]  Open
71
Patel SR. Systemic therapy for advanced soft-tissue sarcomas. Curr Oncol Rep 2002;4:299-304. [PMID: 12044239 DOI: 10.1007/s11912-002-0005-3] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
72
Price JT, Thompson EW. Mechanisms of tumour invasion and metastasis: emerging targets for therapy. Expert Opin Ther Targets 2002;6:217-33. [PMID: 12223082 DOI: 10.1517/14728222.6.2.217] [Citation(s) in RCA: 92] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
PrevPage 2 of 2 12Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA